Nociceptive adenosine A_2A receptor on trigeminal nerves orchestrates CGRP release to regulate the progression of oral squamous cell carcinoma

Abstract

Oral squamous cell carcinoma (OSCC) associated pain commonly predicts adverse events among patients. This clinical feature indicates the engagement of nociceptors on sensory neurons during the development of malignancy. However, it is yet to be determined if targeting oncometabolite-associated nociception processes can hinder OSCC progression. In this study, we reported that nociceptive endings infiltrating both clinical samples and mouse tumor xenografts were associated with poorer clinical outcomes and drove tumor progression in vivo, as evidenced by clinical tissue microarray analysis and murine lingual denervation. We observed that the OSCC microenvironment was characteristic of excessive adenosine due to CD73 upregulation which negatively predicted clinical outcomes in the TCGA-HNSC patient cohort. Notably, such adenosine concentrative OSCC niche was associated with the stimulation of adenosine A_2A receptor (A_2AR) on trigeminal ganglia. Antagonism of trigeminal A_2AR with a selective A_2AR inhibitor SCH58261 resulted in impeded OSCC growth in vivo. We showed that trigeminal A_2AR overstimulation in OSCC xenograft did not entail any changes in the transcription level of CGRP in trigeminal ganglia but significantly triggered the release of CGRP, an effect counteracted by SCH58261. We further demonstrated the pro-tumor effect of CGRP by feeding mice with the clinically approved CGRP receptor antagonist rimegepant which inhibited the activation of ERK and YAP. Finally, we diminished the impact of CGRP on OSCC with istradefylline, a clinically available drug that targets neuronal A_2AR. Therefore, we established trigeminal A_2AR-mediated CGRP release as a promising druggable circuit in OSCC treatment.

References

1. Gargiulo, P.et al.Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores.Ther. Adv. Med Oncol. 11, 175883591881835(2019).
2. Cuffari L.,Tesseroli de Siqueira, J. T., Nemr, K. & Rapaport, A. Pain complaint as the first symptom of oral cancer: a descriptive study.Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endod. 102, 56-61 (2006).
3. Carrillo J. F., Carrillo L. C., Ramirez-Ortega, M. C., Ochoa-Carrillo, F. J. & Oñate-Ocaña, L. F. The impact of treatment on quality of life of patients with head and neck cancer and its association with prognosis.Eur. J. Surg. Oncol. 42, 1614-1621 (2016).
4. Ye, Y.et al.Advances in head and neck cancer pain.J. Dent. Res. 101, 1025(2022).
5. Baliki M. N.& Apkarian, A. V. Nociception, pain, negative moods, and behavior selection.Neuron 87, 474-491 (2015).
6. Taiwo Y. O.& Levine, J. D. Direct cutaneous hyperalgesia induced by adenosine.Neuroscience 38, 757-762 (1990).
7. Borea P. A., Gessi S., Merighi S., Vincenzi F.& Varani, K. Pathological overproduction: the bad side of adenosine.Br. J. Pharm. 174, 1945-1960 (2017).
8. Thuraiaiyah J., Kokoti L., Al-Karagholi, M. A. M. & Ashina, M. Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies.J. Headache Pain. 23, 1-12 (2022).
9. Khayami, R.et al.Role of adenosine signaling in the pathogenesis of head and neck cancer.J. Cell Biochem. 119, 7905-7912 (2018).
10. Bagan, J., Sarrion, G.& Jimenez, Y. Oral cancer: clinical features.Oral. Oncol. 46, 414-417 (2010).
11. Sidders, B.et al.Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response.Clin. Cancer Res. 26, 2176-2187 (2020).
12. Jeon, S. J.et al.Activation of adenosine A2A receptor up-regulates BDNF expression in rat primary cortical neurons.Neurochem. Res. 36, 2259-2269 (2011).
13. Südhof T. C.Neurotransmitter release: the last millisecond in the life of a synaptic vesicle.Neuron 80, 675-690 (2013).
14. Cristóvão-Ferreira, S. et al. A1R-A2AR heteromers coupled to Gs and G i/0 proteins modulate GABA transport into astrocytes.Purinergic Signal. 9, 433-449 (2013).
15. Sebastião, A. M., Macedo, M. P.& Ribeiro, J. A. Tonic activation of A(2A) adenosine receptors unmasks, and of A(1) receptors prevents, a facilitatory action of calcitonin gene-related peptide in the rat hippocampus.Br. J. Pharm. 129, 374-380 (2000).
16. Dixon, A. K., Widdowson, L.& Richardson, P. J. Desensitisation of the adenosine A1 receptor by the A2A receptor in the rat striatum.J. Neurochem. 69, 315-321 (1997).
17. Ribeiro J. A.Adenosine A2A receptor interactions with receptors for other neurotransmitters and neuromodulators.Eur. J. Pharm. 375, 101-113 (1999).
18. Carruthers, A. M.et al.Adenosine A(1) receptor-mediated inhibition of protein kinase A-induced calcitonin gene-related peptide release from rat trigeminal neurons.Mol. Pharm. 59, 1533-1541 (2001).
19. Zhang, Y.et al. Cancer cells co-opt nociceptive nerves to thrive in nutrient-poor environments and upon nutrient-starvation therapies. Cell Metab. 34, 1999-2017.e10 (2022).
20. Kawase, T.et al.Calcitonin gene-related peptide acts as a mitogen for human Gin-1 gingival fibroblasts by activating the MAP kinase signalling pathway.J. Periodontal Res. 34, 160-168 (1999).
21. Jiang, Y.et al.Neuronal TRPV1-CGRP axis regulates bone defect repair through Hippo signaling pathway.Cell Signal. 109, 110779(2023).
22. De Lera Ruiz, M., Lim, Y. H. & Zheng, J. Adenosine A2A receptor as a drug discovery target.J. Med Chem. 57, 3623-3650 (2014).
23. Lam D. K.& Schmidt, B. L. Orofacial pain onset predicts transition to head and neck cancer.Pain 152, 1206-1209 (2011).
24. Fong, L.et al.Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer.Cancer Discov. 10, 40-53 (2020).
25. Chiappori, A.et al.Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.J. Clin. Oncol. 36, 9089-9089 (2018).
26. Ma, S. R.et al.Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.Mol. Cancer 16, 99(2017).
27. Jeske, S. S.et al.Adenosine-producing regulatory B cells in head and neck cancer.Cancer Immunol. Immunother. 69, 1205-1216 (2020).
28. Newton H. S., Chimote A. A., Arnold M. J., Wise-Draper, T. M. & Conforti, L. Targeted knockdown of the adenosine A2A receptor by lipid NPs rescues the chemotaxis of head and neck cancer memory T cells.Mol. Ther. Methods Clin. Dev. 21, 133-143 (2021).
29. Sawynok J.& Liu, X. J. Adenosine in the spinal cord and periphery: Release and regulation of pain.Prog. Neurobiol. 69, 313-340 (2003).
30. Tracey W. D.Nociception.Curr. Biol. 27, R129-R133 (2017).
31. Balood, M.et al.Nociceptor neurons affect cancer immunosurveillance.Nature 611, 405-412 (2022).
32. Toda, M.et al.Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide.Proc. Natl Acad. Sci. USA 105, 13550-13555 (2008).
33. Amit, M.et al.Loss of p53 drives neuron reprogramming in head and neck cancer.Nature 578, 449-454 (2020).
34. Saito A.& Cavalli, V. Signaling over distances.Mol. Cell Proteom. 15, 382-393 (2016).
35. Kawanami, Y.et al.Calcitonin gene-related peptide stimulates proliferation of alveolar epithelial cells.Respir. Res. 10, 8(2009).
36. Russell F. A., King R., Smillie S. J., Kodji X.& Brain, S. D. Calcitonin gene-related peptide: physiology and pathophysiology.Physiol. Rev. 94, 1099-1142 (2014).
37. Dubowchik, G. M., Conway, C. M.& Xin, A. W. Blocking the CGRP pathway for acute and preventive treatment of migraine: the evolution of success.J. Med. Chem. 63, 6600-6623 (2020).
38. Yu, F. X.et al.Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling.Cell 150, 780-791 (2012).
39. Feng, X.et al. A platform of synthetic lethal gene interaction networks reveals that the GNAQ uveal melanoma oncogene controls the hippo pathway through FAK. Cancer Cell 35, 457-472.e5 (2019).
40. Feng, X.et al.Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.Cancer Cell 25, 831-845 (2014).
41. Jiang, Y.et al.GPR39 overexpression in OSCC promotes YAP-sustained malignant progression.J. Dent. Res. 99, 949-958 (2020).
42. Laschinger, M.et al.The CGRP receptor component RAMP1 links sensory innervation with YAP activity in the regenerating liver.FASEB J. 34, 8125-8138 (2020).
43. Zanconato, F., Cordenonsi, M.& Piccolo, S. YAP/TAZ at the roots of cancer.Cancer Cell 29, 783-803 (2016).
44. Roberts P. J.& Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.Oncogene 26, 3291-3310 (2007).
45. Subbiah, V., Baik, C.& Kirkwood, J. M. Clinical development of BRAF plus MEK inhibitor combinations.Trends Cancer 6, 797-810 (2020).
46. Hedberg, M. L.et al.Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.J. Exp. Med. 216, 419-427 (2019).
47. Lumley, C. J.et al.Post-diagnosis aspirin use and survival in veterans with head and neck cancer.Head Neck 41, 1220-1226 (2019).
48. Pang, J.et al.Chronic opioid use following surgery for oral cavity cancer.JAMA Otolaryngol. Head. Neck Surg. 143, 1187-1194 (2017).
49. Caraceni, A.et al.Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.Lancet Oncol. 13, e58-e68 (2012).
50. Viet C. T.& Schmidt, B. L. Biologic mechanisms of oral cancer pain and implications for clinical therapy.J. Dent. Res. 91, 447(2012).
51. Shi, D. D.et al.Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities.Lancet Oncol. 23, e62-e74 (2022).
52. Müller T.The safety of istradefylline for the treatment of Parkinson’s disease.Expert Opin. Drug Saf. 14, 769-775 (2015).
53. Ocheretyaner, E. R., Kofman, M. & Quattrocchi, E. Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults. Drugs Context 11, 2022-3-5 (2022).
54. Szkutnik-Fiedler, D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs—lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies.Pharmaceutics 12, 1-22 (2020).
55. Min, K. C.et al.Atogepant is not associated with clinically meaningful alanine aminotransferase elevations in healthy adults.Clin. Transl. Sci. 14, 599-605 (2021).
56. Rissardo J. P.& Caprara, A. L. F. Gepants for acute and preventive migraine treatment: a narrative review.Brain Sci. 12, 1612(2022).
57. Vijayan D., Young A., Teng M. W.L. & Smyth, M. J. Targeting immunosuppressive adenosine in cancer.Nat. Rev. Cancer 17, 709-724 (2017).
58. Fiore N. T., Debs S. R., Hayes J. P., Duffy S. S.& Moalem-Taylor, G. Pain-resolving immune mechanisms in neuropathic pain.Nat. Rev. Neurol. 19, 199-220 (2023).
59. Faraoni, E. Y.et al.CD73-dependent adenosine signaling through adora2b drives immunosuppression in ductal pancreatic cancer.Cancer Res. 83, 1111-1127 (2023).
60. BP, R.et al.Measurement of the endogenous adenosine concentration in humans in vivo: methodological considerations.Curr. Drug Metab. 9, 679-685 (2008).